Copanlisib (BAY 80-6946) is a potent, selective, and ATP-competitive pan-class I PI3K inhibitor (IC50s: 0.5 nM for PI3Kα, 0.7 nM for PI3Kδ, 3.7 nM for PI3Kβ, and 6.4 nM for PI3Kγ). It exhibits over 2,000-fold selectivity against other kinases, except for mTOR, and demonstrates strong antitumor activity by inhibiting PI3K signaling and inducing tumor regression. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.